Related Experiment Video
Updated: Jul 19, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Immunotherapy for head and neck squamous cell carcinoma]
1Service d'oto-rhino-laryngologie et de chirurgie cervico-faciale, CHUV, 1011 Lausanne. Luc.bron@chuv.ch
Abstract:
In the past decades, prognosis of head and neck squamous cell carcinoma (HNSCC) has not improved despite substantial progress in treatment options. Since antitumoral immunity was described, immunotherapy has shown promising results as an adjunctive treatment in various cancer types. Tumor-associated antigens (TAAs) have been identified and shown to stimulate selective T-cell-mediated antitumoral immune response. This article briefly reviews the work done in the field of immunotherapy of HNSCC in the past few years. It gives confidence that immunotherapy may play an important role in the treatment of head and neck squamous cell carcinoma. Among various TAAs, the family of cancer testis antigens (CTAs) may be promising candidates for specific immune therapy in HNSCC. Ongoing studies will confirm whether CTAs may generate an immune response in clinical vaccine trials.
Insights
Immunotherapy shows promise for head and neck squamous cell carcinoma (HNSCC) treatment. Cancer testis antigens (CTAs) are potential targets for future HNSCC immunotherapy vaccines.
Area of Science:
- Oncology and Immunology
- Cancer Research
Context:
- Prognosis for head and neck squamous cell carcinoma (HNSCC) remains poor despite treatment advances.
- Immunotherapy has emerged as a successful adjunctive treatment for various cancers by harnessing antitumoral immunity.
Purpose:
- To review recent advancements in immunotherapy for HNSCC.
- To explore the potential of tumor-associated antigens (TAAs), particularly cancer testis antigens (CTAs), as targets for HNSCC immunotherapy.
Summary:
- Recent research in HNSCC immunotherapy is reviewed, highlighting its potential role in treatment.
- Tumor-associated antigens (TAAs) can stimulate T-cell-mediated immune responses against cancer.
- Cancer testis antigens (CTAs) are identified as promising candidates for targeted immunotherapy in HNSCC.
Impact:
- Immunotherapy may significantly improve head and neck squamous cell carcinoma treatment outcomes.
- Further clinical trials are needed to validate the efficacy of CTA-based vaccines in HNSCC patients.
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

